Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GRN | P28799 | 4/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284523 | 0.86 | KDM4E (0.41) | KDM4EMAPK14ALDH1A1GRNSORT1 | |
| SCHEMBL283715 | 0.83 | KDM4E (0.39) | KDM4EMAPK14ALDH1A1GRNSORT1 | |
| SCHEMBL283910 | 0.80 | KDM4E (0.44) | KDM4EMAPK14ALDH1A1GRNSORT1 | |
| SCHEMBL12859076 | 0.80 | MAPK14 (0.41) | KDM4EMAPK14ALDH1A1GRNSORT1 | |
| SCHEMBL3843249 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1GRNSORT1POLB | |
| SCHEMBL1924672 | 0.79 | KDM4E (0.42) | KDM4EMAPK14ALDH1A1GRNSORT1 | |
| SCHEMBL13004481 | 0.77 | MAPK14 (0.43) | KDM4EMAPK14ALDH1A1GRNSORT1 | |
| SCHEMBL22505758 | 0.77 | KDM4E (0.41) | KDM4EMAPK14ALDH1A1GRNSORT1 | |
| SCHEMBL282922 | 0.77 | CNR1 (0.49) | KDM4EMAPK14GRNSORT1CNR1 | |
| SCHEMBL16279245 | 0.76 | KDM4E (0.41) | KDM4EALDH1A1GRNSORT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| US-9403815-B2 | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403815-B2 | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-06-27 | — | — | US | disclosed |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | KDM4E 1941/4885MAPK14 2425/4885ALDH1A1 152/4885 |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | IAPP, APP, BACE1 | KDM4E 4398/4885MAPK14 2110/4885ALDH1A1 1605/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | KDM4E 1941/4885MAPK14 2425/4885ALDH1A1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.